SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report)'s stock price fell 4.4% on Tuesday . The company traded as low as $3.68 and last traded at $3.68. 50,630 shares traded hands during mid-day trading, a decline of 44% from the average session volume of 89,960 shares. The stock had previously closed at $3.85.
Analyst Ratings Changes
Separately, Craig Hallum assumed coverage on SOPHiA GENETICS in a research report on Wednesday, December 18th. They set a "buy" rating and a $11.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, SOPHiA GENETICS currently has a consensus rating of "Moderate Buy" and a consensus target price of $7.40.
View Our Latest Research Report on SOPH
SOPHiA GENETICS Price Performance
The company has a current ratio of 3.80, a quick ratio of 3.59 and a debt-to-equity ratio of 0.12. The company's 50-day moving average price is $3.43 and its two-hundred day moving average price is $3.54. The company has a market cap of $262.17 million, a P/E ratio of -3.68 and a beta of 1.03.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the company. Principal Financial Group Inc. increased its stake in SOPHiA GENETICS by 6.3% during the third quarter. Principal Financial Group Inc. now owns 1,455,142 shares of the company's stock valued at $5,290,000 after purchasing an additional 86,764 shares during the last quarter. Federated Hermes Inc. grew its position in shares of SOPHiA GENETICS by 40.5% during the 4th quarter. Federated Hermes Inc. now owns 100,000 shares of the company's stock valued at $312,000 after buying an additional 28,819 shares during the last quarter. Green Alpha Advisors LLC raised its stake in SOPHiA GENETICS by 119.3% during the fourth quarter. Green Alpha Advisors LLC now owns 47,216 shares of the company's stock worth $145,000 after acquiring an additional 25,686 shares during the period. Silverberg Bernstein Capital Management LLC bought a new position in SOPHiA GENETICS in the fourth quarter worth about $70,000. Finally, Dimensional Fund Advisors LP boosted its stake in SOPHiA GENETICS by 23.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 21,619 shares of the company's stock valued at $68,000 after acquiring an additional 4,115 shares during the period. Institutional investors own 31.59% of the company's stock.
About SOPHiA GENETICS
(
Get Free Report)
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.
Further Reading
Before you consider SOPHiA GENETICS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SOPHiA GENETICS wasn't on the list.
While SOPHiA GENETICS currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
